Lambrolizumab CAS NO.1374853-91-4

Our company has been in existence for 10 years since its establishment. We have our own unique team. The company  integrates independent research and development, production and sales. We have established famous brands at home and  abroad. At present, our customers have spread all over the world, we have rich Transportation experience, we aim to  serve customers, to help customers, solve problems for customers. Look forward to working with you!

This humanized receptor-directed monoclonal antibody and anticancer agent (MW = 146.3 kDa; CAS 1374853-91-4), also known by its code name MK-3475, its former name lambrolizumab, and its trade name Keytruda , targets the Programmed Death-1 (PD-1 or Pdcd1) receptor, a well-known negative regulator of T-cell effector mechanisms that limits immune responses against cancer. Having received "Breakthrough Therapy" designation in April, 2013 to expedite its development as a melanoma therapy, pembrolizumab won final FDA approval in September, 2014. Mechanism of Inhibitor Action: An immunoreceptor belonging to the CD28/CTLA-4 family, PD-1 negatively regulates antigen receptor signaling by recruiting the protein tyrosine phosphatase SHP-2, after interacting with either of two ligands, PD-L1 or PD-L2. With its wide range of ligand distribution in the body, PD-1 is significant in nearly every aspect of immune responses (e.g. autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege). Pembrolizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. PD-1 and related target PD-ligand 1 (PD-L1) are normally expressed on the surface of activated T cells, and formation of the PDL1·PD-1 complex inhibits immune activation and reduces T-cell cytotoxic activity when bound. This negative feedback loop maintains normal immune responses by limiting T-cell activity and thereby protecting normal cells during chronic inflammation. Tumor cells can circumvent T-cell– mediated cytotoxicity by expressing PD-L1 on their outer surface or on tumor-infiltrating immune cells to inhibit immune-mediated tumor cell killing. Use of pembrolizumab is indicated in the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab, especially if positive for the BRAFV600 mutation. MK3475 is also highly selective, humanized monoclonal IgG4-k isotype antibody against PD-1 that is designed to block the negative immune regulatory signaling of the PD-1 receptor on T cells. Inhibitor Design: To preparepembrolizumab, the variable region sequences of a very high affinity (Kd = 28 pM) mouse anti-human PD-1 antibody were grafted into a human IgG4 immunoglobulin with a stabilizing Ser-228-Pro alteration in Fc receptors. The IgG4 subtype does not engage Fc receptors and does not activate complement, thereby avoiding cytotoxic effects of the antibody when it binds to the T cells that it is intended to activate. Pharmacokinetics: The recommended dose (2 mg/kg) is administered as an intravenous infusion over 30 minutes every 3 weeks, or until disease progression resumes or toxicity becomes unacceptable. Its steady-state concentration is reached by 18 weeks. (Half-life: 26 days; Clearance: 0.22 L/day)

 

 

      All Key Manufacturers and Suppliers of Baoji Guokang have routine inspections to ensure they are in compliance with the standards set in place during the original Supplier Assessment Inspection.

 

   Production Inspection Process:

Our Group service includes regular and thorough inspections throughout the manufacturing process, eliminating the need to employ additional quality control inspectors.

- Raw material before any production begins

- Pre-production samples to ensure specifications are being met

- In-process to confirm that standards are maintained

- Pre-shipping to ensure that the product arrives to the customer exactly as expected and is packaged

correctly to prevent any damage in transit.

 

   

     We can help operating split shipments, meeting the factory minimum quantity but ship them in 2 or 3 shipments with required gaps among. This allows you to move stock through your business without taking up space and capital.

We will arrange the subsequent shipments from our factory to your warehouse.

We can consolidate your small orders from multiple factories, delivering all at the same time to you or your customers,using the most cost-effective route available. At the time of order placement, we will offer details to you about the volume of each component part and what size container will be used.

 

    We can offer the complete package from concept to delivery; arranging everything up until products arrive at your own door or distribution hub.

   Delivery can be offered.

    - Utilizing your own freight-forwarder

    - FOB to a port in China

    - CIF to a port near you

   Whether you have your own freight-forwarder or you would like to organize shipment; whether you require delivery FOB in China or CIF to a port near you, we are glad to quote and supply whichever way you choose. Please feel free to discuss all options with us.

 

 

 

1.Client is first.We are trying to bring maximum profit to our clients and we only share small.

2.Credibility is the most important.

3.Quality control is our life.

4.Great sense of responsibility.

We will be responsible for not only our products, our clients, our suppliers, also the society.